Table 1.
Baseline and demographic characteristics of the study population (N=87) per treatment arm.
| Characteristic | Mobile health tool intervention group (n=43) | Paper action plan control group (n=44) | |
| Recruited in hospital, n (%) | 21 (49) | 24 (55) | |
| Follow-up in weeks, mean (SD) | 48.3 (12.6) | 49.8 (10.9) | |
| Age (years), mean (SD) | 69.3 (8.8) | 65.9 (8.9) | |
| Male sex, n (%) | 25 (58) | 29 (66) | |
| Postbronchodilator FEV1a (% predicted), mean (SD) | 53.0 (21.5) | 52.1 (19.8) | |
| Medical Research Council dyspnea score, mean (SD) | 2.5 (1.2) | 2.6 (1.3) | |
| Currently smoking, n (%) | 13 (30) | 11 (25) | |
| Use of paper action plan prior to follow-up, n (%) | 11 (26) | 17 (39) | |
| Respiratory drug treatment, n (%) | |||
|
|
Long-acting bronchodilators | 27 (63) | 26 (59) |
|
|
Short-acting bronchodilators | 30 (70) | 31 (71) |
|
|
Inhaled corticosteroids (ICS) | 7 (16) | 13 (30) |
|
|
Long-acting bronchodilators + ICS | 22 (51) | 24 (55) |
| Low education level, n (%) | 19 (44) | 17 (39) | |
| Diagnosis of COPD >5 years, n (%) | 29 (68) | 28 (64) | |
| Currently working, n (%) | 6 (14) | 10 (23) | |
| Relevant comorbidities, n (%) | |||
|
|
Joint disorders | 13 (30) | 13 (30) |
|
|
Cardiac disorders | 12 (28) | 12 (27) |
|
|
Back pain | 8 (19) | 14 (32) |
|
|
Diabetes | 3 (7) | 3 (7) |
|
|
Depression and/or anxiety | 3 (7) | 2 (5) |
aFEV1: forced expiratory volume in 1 second.